Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer

Ying, Kangkang; Bai, Bingjun; Gao, Xing; Xu, Yuzi; Wang, Hangxiang; Xie, Binbin

doi:10.3389/fbioe.2021.670124

Cited by 17 publications

(20 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, each brings its own advantages and disadvantages, and an effective formulation for colon carcinomas has not been developed yet. From this point of view, novel drug delivery systems and nanoparticular drug delivery systems are considered and evaluated as trends and promising approaches in the treatment of colon carcinomas as well as of many other diseases [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

Ünal¹,

Doğan²,

Aktaş³

2022

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

Intestinal cancers are the third most lethal cancers globally, beginning as polyps in the intestine and spreading with a severe metastatic tendency. Chemotherapeutic drugs used in the treatment of intestinal tumors are usually formulated for parenteral administration due to poor solubility and bioavailability problems. Pharmaceutically, clinical failure due to a drug’s wide biodistribution and non-selective toxicity is one of the major challenges of chemotherapy. In addition, parenteral drug administration in chronic diseases that require long-term drug use, such as intestinal tumors, is challenging in terms of patient compliance and poses a burden in terms of health economy. Especially in the field of chemotherapy research, oral chemotherapy is a subject that has been intensively researched in recent years, and developments in this field will provide serious breakthroughs both scientifically and socially. Development of orally applicable nanodrug formulations that can act against diseases seen in the distant region of the gastrointestinal tract (GIT), such as intestinal tumor, brings with it a series of difficulties depending on the drug and/or GIT physiology. The aim of this study is to develop an oral nanoparticle drug delivery system loaded with docetaxel (DCX) as an anticancer drug, using poly(lactic-co-glycolic acid) (PLGA) as nanoparticle material, and modified with chitosan (CS) to gain mucoadhesive properties. In this context, an innovative nanoparticle formulation that can protect orally administered DCX from GIT conditions and deliver the drug to the intestinal tumoral region by accumulating in mucus has been designed. For this purpose, DCX-PLGA nanoparticles (NPs) and CS/DCX-PLGA NPs were prepared, and their in vitro characteristics were elucidated. Nanoparticles around 250–300 nm were obtained. DCX-PLGA NPs had positive surface charge with CS coating. The formulations have the potential to deliver the encapsulated drug to the bowel according to the in vitro release studies in three different simulated GIT fluids for approximately 72 h. Mucin interaction and penetration into the artificial mucus layer were also investigated in detail, and the mucoadhesive and mucus-penetration characteristics of the formulations were examined. Furthermore, in vitro release kinetic studies of the NPs were elucidated. DCX-PLGA NPs were found to be compatible with the Weibull model, and CS/DCX-PLGA NPs were found to be compatible with the Peppas–Sahlin model. Within the scope of in vitro cytotoxicity studies, the drug-loaded NPs showed significantly higher cytotoxicity than a DCX solution on the HT-29 colon cell line, and CS/DCX-PLGA showed the highest cytotoxicity (p < 0.05). According to the permeability studies on the Caco-2 cell line, the CS/DCX-PLGA formulation increased permeability by 383% compared to free DCX (p < 0.05). In the light of all results, CS/DCX-PLGA NPs can offer a promising and innovative approach as an oral anticancer drug-loaded nanoformulation for intestinal tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

Ünal¹,

Doğan²,

Aktaş³

2022

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

show abstract

“…Most of the LNPs employed for the treatment of colorectal cancer are via oral route. It was observed that the LNPs are absorbed from the intestinal lumen into the circulation of colorectal region through endocytosis or via carrier-mediated transport [ 159 ]. Similarly, for treating hepatocellular carcinoma (liver cancer), LNPs are presently under pre-clinical and clinical trials.…”

Section: Clinical Statusmentioning

confidence: 99%

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy

Chaudhuri

Kumar

Shaik

et al. 2022

IJMS

View full text Add to dashboard Cite

Triple-negative breast cancer is considered the most aggressive type of breast cancer among women and the lack of expressed receptors has made treatment options substantially limited. Recently, various types of nanoparticles have emerged as a therapeutic option against TNBC, to elevate the therapeutic efficacy of the existing chemotherapeutics. Among the various nanoparticles, lipid-based nanoparticles (LNPs) viz. liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid nanocarriers, and lipid–polymer hybrid nanoparticles are developed for cancer treatment which is well confirmed and documented. LNPs include various therapeutic advantages as compared to conventional therapy and other nanoparticles, including increased loading capacity, enhanced temporal and thermal stability, decreased therapeutic dose and associated toxicity, and limited drug resistance. In addition to these, LNPs overcome physiological barriers which provide increased accumulation of therapeutics at the target site. Extensive efforts by the scientific community could make some of the liposomal formulations the clinical reality; however, the relatively high cost, problems in scaling up the formulations, and delivery in a more targetable fashion are some of the major issues that need to be addressed. In the present review, we have compiled the state of the art about different types of LNPs with the latest advances reported for the treatment of TNBC in recent years, along with their clinical status and toxicity in detail.

show abstract

“…The formulation was well tolerated; however, there is a need for further clinical studies on the combination of the formulation with fluoropyrimidines [ 109 ]. Ying et al reported the oxaliplatin which was encapsulated into PEG-coated cationic liposomes [ 110 ] and long-circulating liposomes (PEG-liposomal oxaliplatin). The effects of PEG-liposomal oxaliplatin on a tumour formed by a human CRC cell line (SW480) in female BALB/c nude mice were studied.…”

Section: Nanoparticles Loaded With Platinum Drugs For Colorectal Canc...mentioning

confidence: 99%

Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy

Buyana

Naki

Alven

et al. 2022

IJMS

View full text Add to dashboard Cite

Colorectal cancer is a common cancer in both men and women. Numerous studies on the therapeutic effectiveness of nanoparticles against colorectal cancer have been reported. Platinum treatments as well as other medications comprising of nanoparticles have been utilized. Drug resistance restricts the use of platinum medicines, despite their considerable efficacy against a variety of cancers. This review reports clinically licensed platinum medicines (cisplatin, carboplatin, and oxaliplatin) combined with various nanoparticles that have been evaluated for their therapeutic efficacy in the treatment of colorectal cancer, including their mechanism of action, resistance, and limitations.

show abstract

Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer

Cited by 17 publications

References 192 publications

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

Orally administered docetaxel-loaded chitosan-decorated cationic PLGA nanoparticles for intestinal tumors: formulation, comprehensive in vitro characterization, and release kinetics

Lipid-Based Nanoparticles as a Pivotal Delivery Approach in Triple Negative Breast Cancer (TNBC) Therapy

Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy

Contact Info

Product

Resources

About